Completed

VI-0521 Safety and Efficacy in Adult Obesity with Related Co-Morbidities

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This phase 3 study aims to evaluate the safety and effectiveness of a treatment in helping adults with obesity and related health conditions achieve at least 5% weight loss or more after 56 weeks.

What is being tested

VI-0521

Drug
Who is being recruted

Body Weight+10

+ Diabetes Mellitus

+ Diabetes Mellitus, Type 2

From 18 to 70 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Placebo-ControlledPhase 3
Interventional
Study Start: November 2007
See protocol details

Summary

Principal SponsorVIVUS LLC
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: November 1, 2007

Actual date on which the first participant was enrolled.

The purpose of this study is to evaluate the efficacy and safety of VI0521 compared to placebo in treatment of obesity in an adult population with obesity related co-morbid conditions.

Official TitleA Phase III Randomized, Double-Blind, Placebo Controlled Multicenter Study to Determine the Safety and Efficacy of VI-0521 in the Treatment of Obesity in Adults With Obesity-Related Co-Morbid Conditions
Principal SponsorVIVUS LLC
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

2487 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 70 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Body WeightDiabetes MellitusDiabetes Mellitus, Type 2Endocrine System DiseasesMetabolic DiseasesNutrition DisordersNutritional and Metabolic DiseasesObesitySigns and SymptomsPathological Conditions, Signs and SymptomsOvernutritionGlucose Metabolism DisordersOverweight

Criteria

Inclusion Criteria: * Informed Consent * BMI ≥ 27 (no lower BMI limit for Type 2 diabetics) * 70 years of age or less * Have 2 or more of the following obesity-related co-morbid conditions: * Systolic blood pressure 140-160 mmHg (130-160 if diabetic); * Diastolic blood pressure 90-100 mmHg (85-100 if diabetic); * Requirement for 2 or more medications to achieve control (\<140/90 mmHg) * Triglyceride level between 200-400 mg/dL or requirement for 2 or more medications to achieve control (\<200 mg/dL) * At lease one of the following metabolic criteria: * Fasting blood glucose level \> 100 mg/dL * Glucose level \> 140 mg/dL * Diagnosis of type 2 diabetes * Waist circumference ≥ 102 cm for men or ≥88 cm for women Exclusion Criteria: * Stroke/MI/unstable cardiovascular disease within 6 months * Clinically significant renal, hepatic or psychiatric disease * Unstable thyroid disease or replacement therapy * Nephrolithiasis * Obesity of known genetic or endocrine origin * Participation in a formal weight loss program or lifestyle intervention * Glaucoma or intraocular pressure * Pregnancy or breastfeeding * Drug or Alcohol abuse * Smoking cessation within previous 3 months or plans to quit smoking during study * Eating disorders * Cholelithiasis within past 6 months * Excluded medications * Type 1 diabetes or use of any antidiabetic medication other than metformin * Previous bariatric surgery * Bipolar disorder or psychosis * Steroid hormone therapy * Systolic blood pressure \> 160 mmHg, diastolic blood pressure \> 100 mmHg * Creatinine clearance \< 60 mL/minute

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

3 intervention groups are designated in this study

33.333% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental
high dose experimental treatment

Group II

Experimental
mid dose experimental treatment

Group III

Placebo
Placebo

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 6 locations

Suspended

Research Site

Birmingham, United StatesOpen Research Site in Google Maps
Suspended

Research Site

Ridgefield, United States
Suspended

Research Site

New York, United States
Suspended

Research Site

Durham, United States
Completed6 Study Centers
VI-0521 Safety and Efficacy in Adult Obesity with Related Co-Morbidities | PatLynk